Search

everythinglearnresearchcommunity

for

Search:↓

Selenium sulfide shampoo helped with a sore scalp but may cause hair root damage. Users experienced hair loss with selenium sulfide and ketoconazole, suggesting reducing use if hair loss occurs.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

User has seborrhoeic dermatitis causing hair loss. They are using Ketoconazole shampoo and may use selenium sulfide shampoo.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

The conversation discusses the potential of Sanguisorba Officinalis Root Extract as a treatment for hair loss by inhibiting FGF-5. The user also mentions the product évolis, which is based on this extract but is only available in the US and Australia.

CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.

Breezula shows promise in stabilizing hair loss and potentially promoting regrowth at the one-year mark, offering hope for those who can't tolerate 5AR inhibitors. Its local targeting of androgen receptors could be a significant advancement if it avoids systemic side effects.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.

The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

A 21-year-old is experiencing aggressive hair loss and dandruff, possibly due to seborrheic dermatitis, and is using pumpkin seed oil, scalp massages, and anti-dandruff shampoo as treatments. They are hesitant to use prescribed Finasteride and Minoxidil and have noticed some improvement after stopping Serenoa capsules.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Some people have low sulfotransferase enzyme levels, affecting their response to minoxidil. Lifestyle factors, genetics, and diet, like MSM intake, might influence these enzyme levels.